NASDAQ:PRTKParatek Pharmaceuticals Stock Price, Forecast & News

Paratek Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PRTK stock has increased by 17.5% and is now trading at $4.57. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Paratek Pharmaceuticals.

Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Paratek Pharmaceuticals.

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) posted its earnings results on Monday, May, 11th. The specialty pharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.80) by $0.14. The specialty pharmaceutical company earned $7.92 million during the quarter, compared to the consensus estimate of $7.75 million. Paratek Pharmaceuticals had a negative net margin of 528.28% and a negative return on equity of 5,327.73%. View Paratek Pharmaceuticals' earnings history.

Paratek Pharmaceuticals updated its FY 2020 Pre-Market earnings guidance on Monday, May, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $75-80 million, compared to the consensus revenue estimate of $81.12 million.

6 Wall Street analysts have issued 12-month price targets for Paratek Pharmaceuticals' stock. Their forecasts range from $6.00 to $36.00. On average, they anticipate Paratek Pharmaceuticals' share price to reach $18.50 in the next year. This suggests a possible upside of 304.8% from the stock's current price. View analysts' price targets for Paratek Pharmaceuticals.

Media headlines about PRTK stock have been trending extremely negative recently, according to InfoTrie. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Paratek Pharmaceuticals earned a coverage optimism score of -4.0 on InfoTrie's scale. They also gave media stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutParatek Pharmaceuticals.

Some companies that are related to Paratek Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Aduro BioTech (ADRO), Verastem (VSTM), TherapeuticsMD (TXMD), Energy Transfer LP Unit (ET), EXACT Sciences (EXAS), Exelixis (EXEL), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

Paratek Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.68%), Rock Springs Capital Management LP (3.54%), General American Investors Co. Inc. (1.89%), Granahan Investment Management Inc. MA (1.66%), State Street Corp (1.54%) and Water Island Capital LLC (0.83%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Jeffrey Stein, Michael Bigham, Randall B Brenner, Thomas John Dietz and William M Haskel. View institutional ownership trends for Paratek Pharmaceuticals.

PRTK stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, JPMorgan Chase & Co., Arbiter Partners Capital Management LLC, Water Island Capital LLC, Morgan Stanley, State Street Corp, Parametric Portfolio Associates LLC, and Raymond James & Associates. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Evan Loh, Michael Bigham, Randall B Brenner, and William M Haskel. View insider buying and selling activity for Paratek Pharmaceuticals.

PRTK stock was bought by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Balyasny Asset Management LLC, General American Investors Co. Inc., Nuveen Asset Management LLC, BlackRock Inc., Trellus Management Company LLC, Connor Clark & Lunn Investment Management Ltd., and HighTower Advisors LLC. View insider buying and selling activity for Paratek Pharmaceuticals.

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PRTK stock can currently be purchased for approximately $4.57.

Paratek Pharmaceuticals has a market capitalization of $197.11 million and generates $16.54 million in revenue each year. The specialty pharmaceutical company earns $-128,790,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis. Paratek Pharmaceuticals employs 101 workers across the globe.

The official website for Paratek Pharmaceuticals is www.paratekpharma.com.

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]